Divis Laboratories Limited (NSE: DIVISLAB, BSE: 532488) is a Hyderabad, Telangana-based company in the Pharmaceutical CDMO and CRO Services industry. With a market capitalisation of ₹3,01,758 Cr, it ranks #31 by market cap among the 6,197 Indian listed companies on FinBizNet, and #1 of 11 in Pharmaceutical CDMO and CRO Services. At ₹11,442.00 (as of 16 Nov 2026), the share price is 3.2% below its 52-week high of ₹11,824.00 and 102.6% above its 52-week low of ₹5,647.50. The share price is up 71.9% over one year and up 34.6% over three months.
| Current Price | ₹11,442.00 |
|---|---|
| Market Cap | ₹3,01,758 Cr |
| NSE Symbol | DIVISLAB |
| BSE Code | 532488 |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services |
| Sub-Industry | Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services |
| P/E Ratio | 118.4 |
| Return on Equity | 16.19% |
| Return on Assets | 10.07% |
| 52-Week Range | ₹5,647.50 – ₹11,824.00 |
| 1-Year Price Change | +71.9% |
| 3-Month Price Change | +34.6% |
| Beta (1Y) | 0.21 |
| Dividend Yield | 0.26% |
| Headquarters | Hyderabad, Telangana |
| Website | www.divislabs.com |
| Revenue | ₹3,676 Cr |
|---|---|
| Net Profit | ₹1,127 Cr |
| Net Margin | 30.7% |
| EPS (Basic) | ₹42.49 |
| Basis | consolidated |
Figures in ₹ crore, parsed from the company's exchange filing (XBRL).
Divis Laboratories Limited reported revenue of ₹3,676 Cr in Q2 FY27, up 35.4% from ₹2,715 Cr in Q2 FY26 and up 19.4% from ₹3,080 Cr in Q1 FY27. It posted a net profit of ₹1,127 Cr for the quarter, against a net profit of ₹689 Cr in Q2 FY26 (up 63.6%). Across the 7 quarters from Q4 FY25 to Q2 FY27, quarterly revenue ranged from ₹2,410 Cr (Q1 FY26) to ₹3,676 Cr (Q2 FY27). The company was profitable in each of these 7 quarters.
| Quarter | Revenue | Net Profit | Net Margin |
|---|---|---|---|
| Q2 FY27 | ₹3,676 Cr | ₹1,127 Cr | 30.7% |
| Q1 FY27 | ₹3,080 Cr | ₹902 Cr | 29.3% |
| Q4 FY26 | ₹2,831 Cr | ₹751 Cr | 26.5% |
| Q3 FY26 | ₹2,604 Cr | ₹583 Cr | 22.4% |
| Q2 FY26 | ₹2,715 Cr | ₹689 Cr | 25.4% |
| Q1 FY26 | ₹2,410 Cr | ₹545 Cr | 22.6% |
| Q4 FY25 | ₹2,585 Cr | ₹662 Cr | 25.6% |
Consolidated figures (₹ crore, XBRL filings).
Promoters held 51.88% of Divis Laboratories Limited's shares as of Sept 2026, against 51.89% in Sept 2025 (−0.01 percentage points). Delivery averaged 56.9% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).
Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as lutein and vitamins used in the food, beverage, dietary supplement, pet food, and feed industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India.
1. Segment Adjustment-This segment manufactures and sells active pharmaceutical ingredients and intermediates. 2. Pharmaceuticals-0
1. Active Pharmaceutical Ingredients, Intermediates and Nutraceutical Ingredients-100%
| Company | Market Cap | P/E | ROE | Latest Qtr Revenue | 1Y Change |
|---|---|---|---|---|---|
| Divis Laboratories Limited | ₹3,01,758 Cr | 118.4 | 16.19% | ₹3,676 Cr | +71.9% |
| Anthem Biosciences Limited | ₹53,926 Cr | 90.1 | 19.45% | ₹594 Cr | +34.5% |
| Sai Life Sciences Limited | ₹40,755 Cr | 116.1 | 15.13% | ₹659 Cr | +120.3% |
| Onesource Specialty Pharma Limited | ₹18,138 Cr | n/m | -1.26% | ₹516 Cr | -9.4% |
| Cohance Lifesciences Ltd | ₹17,756 Cr | 100.6 | 5.11% | ₹477 Cr | -35.2% |
| Syngene International Ltd. | ₹17,630 Cr | 56.9 | 6.62% | ₹833 Cr | -27.9% |
| Jubilant Pharmova Ltd | ₹15,556 Cr | 39.1 | 5.96% | ₹2,370 Cr | -14.5% |
| Concord Biotech Ltd | ₹12,495 Cr | 24.2 | 13.54% | ₹309 Cr | -14.8% |
| Blue Jet Healthcare Ltd | ₹10,140 Cr | 38 | 19.88% | ₹376 Cr | -9.8% |
Listed by market capitalisation. Ratios are shown for context only.
Divis Laboratories Limited is trading at ₹11,442.00, with a market capitalisation of ₹3,01,758 Cr.
Divis Laboratories Limited operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Life Sciences Tools and Services space (Life Sciences Tools and Services > Pharmaceutical CDMO and CRO Services).
Divis Laboratories Limited has a P/E of 118.4 and a return on equity of 16.19%.
Divis Laboratories Limited is listed on the NSE under the symbol DIVISLAB and on the BSE under the scrip code 532488.
Divis Laboratories Limited's share price is up 71.9% over one year and up 34.6% over three months. Its 52-week range is ₹5,647.50 to ₹11,824.00.
In Q2 FY27, Divis Laboratories Limited reported revenue of ₹3,676 Cr and net profit of ₹1,127 Cr, with basic EPS of ₹42.49 (consolidated, parsed from the company's exchange filing).
Divis Laboratories Limited reported revenue of ₹3,676 Cr in Q2 FY27, up 35.4% from ₹2,715 Cr in Q2 FY26 and up 19.4% from ₹3,080 Cr in Q1 FY27.
Promoters held 51.88% of Divis Laboratories Limited's shares as of Sept 2026, against 51.89% in Sept 2025 (−0.01 percentage points).
Data as of 16 Nov 2026. Descriptive market data only — not investment advice.